Rifampicin/isoniazid/pyrazinamide

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 12:32, 7 December 2010 (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: InChI1->InChI StdInChI StdInChIKey.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 12:32, 7 December 2010 by Beetstra (talk | contribs) (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: InChI1->InChI StdInChI StdInChIKey.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Rifampicin/isoniazid/pyrazinamide" – news · newspapers · books · scholar · JSTOR (December 2009) (Learn how and when to remove this message)

Pharmaceutical compound

Rifampicin/isoniazid/pyrazinamide
Combination of
Rifampicin	Rifamycin antibiotic
Isoniazid	First-line anti-tuberculosis medication
Pyrazinamide	Anti-tuberculosis medication
Clinical data
Routes of administration	Oral
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
ChemSpider	10468813
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES CN1CCN(CC1)/N=C/c2c(O)c3c5C(=O)4(C)O/C=C/(OC)(C)(OC(C)=O)(C)(O)(C)(O)(C)\C=C\C=C(\C)C(=O)Nc2c(O)c3c(O)c(C)c5O4
InChI InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1 Key:JQXXHWHPUNPDRT-WLSIYKJHSA-N

Rifater is a fixed dose combination tablet manufactured by Aventis used in the treatment of tuberculosis. Each tablet contains 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide.

It is used in the first two months of tuberculosis treatment. The dose given depends on the patient's weight:

up to 40 kg, 3 tablets daily;
40 to 49 kg, 4 tablets daily;
50 to 64 kg, 5 tablets daily;
65 kg or more, 6 tablets daily.

Rifater should not be used in children (the doses are wrong for them).

The purpose of the fixed dose combination is to make it easier for patients to take their medication; but also to ensure that if patients forget to take one or two of their drugs, they do not then develop resistance to the remaining drugs.

Misplaced Pages

Rifampicin/isoniazid/pyrazinamide

See also